(Q49536984)

21 February 2018

title

Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer (English)

1 reference

21 February 2018

1 reference

Min Young Baek

1

1 reference

21 February 2018

Hee Kyung Ahn

2

1 reference

21 February 2018

Kyu Ree Park

3

1 reference

21 February 2018

Hwa-Sun Park

4

1 reference

21 February 2018

Shin Myung Kang

5

1 reference

21 February 2018

Inkeun Park

6

1 reference

21 February 2018

Young Saing Kim

7

1 reference

21 February 2018

Junshik Hong

8

1 reference

21 February 2018

Sun Jin Sym

9

1 reference

21 February 2018

Jinny Park

10

1 reference

21 February 2018

Jae Hoon Lee

11

1 reference

21 February 2018

Dong Bok Shin

12

1 reference

21 February 2018

Eun Kyung Cho

13

1 reference

21 February 2018

publication date

20 April 2016

1 reference

21 February 2018

The Korean journal of internal medicine

published in

1 reference

21 February 2018

volume

33

1 reference

21 February 2018

issue

1

1 reference

21 February 2018

page(s)

168-175

1 reference

21 February 2018

Creative Commons Attribution-NonCommercial 3.0 Unported

copyright license

start time

20 April 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

The Importance of Brain Metastasis in EGFR Mutation Positive NSCLC Patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5768530

Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5768530

Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5768530

EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5768530

The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5768530

Involvement of epidermal growth factor receptor overexpression in the promotion of breast cancer brain metastasis.

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5768530

Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5768530

"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5768530

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5768530

EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5768530

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5768530

Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5768530

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5768530

Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5768530

Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: integrating with lung specific GPA score

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5768530

Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5768530

EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases?

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5768530

EGFR mutation and brain metastasis in pulmonary adenocarcinomas

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5768530

EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5768530

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5768530

Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5768530

A note on quantifying follow-up in studies of failure time

14 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27093978

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3904/KJIM.2015.158

1 reference

21 February 2018

PMC publication ID

5768530

1 reference

21 February 2018

PubMed publication ID

27093978

1 reference

21 February 2018